Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wisplinghoff

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|January 27, 2010
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolatesPaul G Higgins, Will Stubbings, Hilmar Wisplinghoff, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2000
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strainsB Heinemann, H Wisplinghoff, M Edmond, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2003
Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United StatesHilmar Wisplinghoff, Harald Seifert, Richard P Wenzel, et al.
Emerging Infectious Diseases|November 12, 2003
Small colony variants of Staphylococcus aureus and pacemaker-related infectionHarald Seifert, Hilmar Wisplinghoff, Petra Schnabel, et al.
Journal of Clinical Microbiology|October 1, 2010
gyrB multiplex PCR to differentiate between Acinetobacter calcoaceticus and Acinetobacter genomic species 3Paul G Higgins, Marlene Lehmann, Hilmar Wisplinghoff, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2004
In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strainsPaul G Higgins, Hilmar Wisplinghoff, Danuta Stefanik, et al.
Journal of Clinical Microbiology|May 15, 1999
Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patientsH Wisplinghoff, R R Reinert, O Cornely, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2004
Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumanniiPaul G Higgins, Hilmar Wisplinghoff, Danuta Stefanik, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 14, 2007
A PCR-based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TUP G Higgins, H Wisplinghoff, O Krut, et al.
Mycoses|November 19, 2015
1,3-ß-D-glucan concentrations in blood products predict false positive post-transfusion resultsB Liss, O A Cornely, D Hoffmann, et al.
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|January 27, 2010
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolatesPaul G Higgins, Will Stubbings, Hilmar Wisplinghoff, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2000
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strainsB Heinemann, H Wisplinghoff, M Edmond, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2003
Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United StatesHilmar Wisplinghoff, Harald Seifert, Richard P Wenzel, et al.
Emerging Infectious Diseases|November 12, 2003
Small colony variants of Staphylococcus aureus and pacemaker-related infectionHarald Seifert, Hilmar Wisplinghoff, Petra Schnabel, et al.
Journal of Clinical Microbiology|October 1, 2010
gyrB multiplex PCR to differentiate between Acinetobacter calcoaceticus and Acinetobacter genomic species 3Paul G Higgins, Marlene Lehmann, Hilmar Wisplinghoff, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2004
In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strainsPaul G Higgins, Hilmar Wisplinghoff, Danuta Stefanik, et al.
Journal of Clinical Microbiology|May 15, 1999
Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patientsH Wisplinghoff, R R Reinert, O Cornely, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2004
Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumanniiPaul G Higgins, Hilmar Wisplinghoff, Danuta Stefanik, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 14, 2007
A PCR-based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TUP G Higgins, H Wisplinghoff, O Krut, et al.
Mycoses|November 19, 2015
1,3-ß-D-glucan concentrations in blood products predict false positive post-transfusion resultsB Liss, O A Cornely, D Hoffmann, et al.
Pageof 11